Miglustat is a pharmaceutical agent primarily used in the treatment of certain rare metabolic disorders such as Gaucher's disease type 1 and Niemann-Pick disease type C. It functions as an inhibitor of the enzyme glucosylceramide synthase, thereby reducing the production of glucosylceramide, a lipid that accumulates in patients with these disorders.
